Results 111 to 120 of about 48,845 (222)

Cardiotoxicity of Anthracyclines and HER2‐Targeted Therapies: Current Insights, Predictive AI Models, Preventive Strategies, and a Proposed AI‐Assisted Cardio‐Oncology Pathway

open access: yesCancer Reports, Volume 9, Issue 11, November 2026.
ABSTRACT Background Advances in hematology‐oncology have substantially improved survival among patients with cancer. However, longer survival has been accompanied by an increasing burden of cancer therapy‐related cardiovascular toxicity (CTR‐CVT), which contributes to overall morbidity and mortality among cancer survivors.
Philippe Attieh   +6 more
wiley   +1 more source

Sunitinib-induced thyrotoxicosis - a not so rare entity

open access: yes, 2015
Background/Aim: The tyrosine kinase inhibitor (TKI) sunitinib malate is nowadays a standard first-line treatment option for patients with metastatic clear-cell renal cell carcinoma (mRCC).
Jazvić, Marijana   +8 more
core   +1 more source

The Effect of Adenosine Triphosphate on Oral Mucosity in Rats due to Sunitinib Administration

open access: yes, 2021
Sunitinib, a common drug used in cancer treatment, is a multi-targeted tyrosine kinase inhibitor. It is argued that sunitinib-associated oral mucositis is caused by VEGF inhibition.
Suleyman, Halis   +9 more
core  

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1338-1347, November 2026.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara   +20 more
wiley   +1 more source

sFRP-4 regulated by n6‑methyladenosine writer ZC3H13 attenuates sunitinib resistance of renal cell carcinoma via inactivating Wnt/β-catenin pathway

open access: yesScientific Reports
Sunitinib, a first-line tyrosine kinase inhibitor, is widely used for renal cell carcinoma (RCC) therapy; however, sunitinib resistance compromises clinical efficacy. N6-methyladenosine (m6A), the most prevalent internal RNA modification, plays a crucial
Cheng Xu   +5 more
doaj   +1 more source

Serum sodium as a potential biomarker for immunotherapy response in metastatic RCC—real‐world evidence from a German multicentre cohort

open access: yesClinical &Translational Immunology, Volume 15, Issue 11, 2026.
Abstract Objectives Sodium is increasingly recognised as a modulator of immune function, and higher baseline serum sodium has been linked to improved outcomes with immune checkpoint inhibitor (IO)‐based therapy in post hoc analyses of randomised trials.
Alix Tschirhart   +18 more
wiley   +1 more source

UPLC‐MS/MS, Transcriptomics Combined With In Vitro and In Vivo Experiments Verify the Mechanism of Yigong San Inducing Ferroptosis in Gastric Cancer

open access: yesFood Science &Nutrition, Volume 14, Issue 11, November 2026.
This graphical abstract summarizes the inhibitory effect of Yigong San (YGS) on gastric cancer proliferation and the underlying mechanisms. UPLC‐MS/MS identified the active components of YGS, thereby providing a basis for its pharmacological effects.
Doudou Lu   +8 more
wiley   +1 more source

Curative‐Intent Pancreatectomy for Pancreatic Metastasis From Renal Cell Carcinoma 30 Years After Nephrectomy Following Lenvatinib Plus Pembrolizumab Therapy: A Case Report

open access: yesIJU Case Reports, Volume 9, Issue 6, November 2026.
ABSTRACT Introduction Renal cell carcinoma (RCC) is the most common primary site of pancreatic metastases, and complete resection confers a favorable prognosis. Lenvatinib plus pembrolizumab (LEN + PEM) is standard first‐line therapy for advanced RCC; however, induction therapy before resection of pancreatic metastasis has not been reported.
Yuta Kaneko   +9 more
wiley   +1 more source

Cabozantinib Monotherapy for Metastatic Renal Cell Carcinoma Involving Hemodialysis: Two Case Reports

open access: yesIJU Case Reports, Volume 9, Issue 6, November 2026.
ABSTRACT Introduction Data on cabozantinib monotherapy for metastatic renal cell carcinoma in patients requiring hemodialysis are scarce. We present two cases: initiation before hemodialysis with subsequent continuation and initiation during maintenance hemodialysis.
Taketoshi Nara   +6 more
wiley   +1 more source

Sunitinib malate induces cell death in adult human cardiac progenitor cells

open access: yesCurrent Research in Toxicology
Sunitinib malate is known to cause cardiotoxicity in a sub-population of patients, with heart failure seen in more severe cases. Cardiac progenitor cells (CPCs) have been identified in adult human myocardium and contribute to overall tissue maintenance ...
Robert Walmsley   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy